Retinoid receptors in ovarian cancer: Expression and prognosis

Annals of Oncology

Volumn 16, Issue 9, 2005, Pages 1477-1487

  Kaiser, P C ^a,b   Korner M ^b   Kappeler, A ^b   Aebi, Stefan ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Nuclear receptors; Ovarian neoplasms; Prognostic factors; Retinoic acid receptors

Indexed keywords

MESSENGER RNA; PROTEIN P53; RETINOIC ACID RECEPTOR; RETINOID; RETINOID X RECEPTOR; RETINOID X RECEPTOR ALPHA; RETINOID X RECEPTOR BETA; RETINOID X RECEPTOR GAMMA;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CORRELATION COEFFICIENT; DISEASE SEVERITY; DRUG RECEPTOR BINDING; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; OVARIECTOMY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGED; BASE SEQUENCE; DNA PRIMERS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; RECEPTORS, RETINOIC ACID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 24044500329     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi265     Document Type: Article

References (60)

1. Jemal A, Tiwari RC, Murray T et al. Cancer statistics. CA Cancer J Clin 2004; 54: 8-29.
2. Schüler G, Bopp M. Ovar und Adnexe. In: Schüler G, Bopp M (eds): Atlas der Krebsmortalität in der Schweiz. Basel: Birkhäuser 1997; 151-154.
3. Vaidya AP, Curtin JP. The follow-up of ovarian cancer. Semin Oncol 2003; 30: 401-412.
4. Mangelsdorf D, Umesono K, Evans R. The retinoid receptors. In Sporn M, Roberts A, Goodman D (eds): The Retinoids, 2 edn. New York: Raven Press 1994; 319-350.
5. Evans R. The steroid and thyroid hormone receptor superfamily. Science 1988; 13: 889-895.
6. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001; 1: 181-193.
7. Wolbach S, Howe P. Tissue changes following deprivation of fat-soluble A-vitamin. J Exp Med 1925; 42: 753-778.
8. Dragnev KH, Rigas JR, Dmitrovsky E. The retinoids and cancer prevention mechanisms. Oncologist 2000; 5: 361-368.
9. Einspahr JG, Stratton SP, Bowden GT, Alberts DS. Chemoprevention of human skin cancer. Crit Rev Oncol Hematol 2002; 41: 269-285.
10. Bertone ER, Hankinson SE, Newcomb PA et al. A population-based case-control study of carotenoid and vitamin A intake and ovarian cancer (United States). Cancer Causes Control 2001; 12: 83-90.
11. Huncharek M, Klassen H, Kupelnick B. Dietary beta-carotene intake and the risk of epithelial ovarian cancer: A meta-analysis of 3,782 subjects from five observational studies. In Vivo 2001; 15: 339-343.
12. Cramer DW, Kuper H, Harlow BL, Titus-Ernstoff L. Carotenoids, antioxidants and ovarian cancer risk in pre- and postmenopausal women. Int J Cancer 2001; 94: 128-134.
13. Salazar-Martinez E, Lazcano-Ponce EC, Lira G et al. Nutritional determinants of epithelial ovarian cancer risk: A case-control study in Mexico. Oncology 2002; 63: 151-157.
14. Zhang M, Lee AH, Binns CW. Reproductive and dietary risk factors for epithelial ovarian cancer in China. Gynecol Oncol 2004; 92: 320-326.
15. Veronesi U, De Palo G, Marubini E et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 1999; 91: 1847-1856.
16. De Palo G, Mariani L, Camerini T et al. Effect of fenretinide on ovarian carcinoma occurrence. Gynecol Oncol 2002; 86: 24-27.
17. Zhang D, Holmes WF, Wu S et al. Retinoids and ovarian cancer. J Cell Physiol 2000; 185: 1-20.
18. Kalli KR, Devine KE, Cabot MC et al. Heterogeneous role of caspase-8 in fenretinide-induced apoptosis in epithelial ovarian carcinoma cell lines. Mol Pharmacol 2003; 64: 1434-1443.
19. Holmes WF, Soprano DR, Soprano KJ. Elucidation of molecular events mediating induction of apoptosis by synthetic retinoids using a CD437-resistant ovarian carcinoma cell line. J Biol Chem 2002; 277: 45408-45419.
20. Holmes WF, Soprano DR, Soprano KJ. Early events in the induction of apoptosis in ovarian carcinoma cells by CD437: Activation of the p38 MAP kinase signal pathway. Oncogene 2003; 22: 6377-6386.
21. Vuocolo S, Purev E, Zhang D et al. Protein phosphatase 2A associates with Rb2/p130 and mediates retinoic acid-induced growth suppression of ovarian carcinoma cells. J Biol Chem 2003; 278: 41881-41889.
22. Mehta K. Retinoids as regulators of gene transcription. J Biol Regul Homeost Agents 2003; 17: 1-12.
23. Crowe DL, Kim R, Chandraratna RA. Retinoic acid differentially regulates cancer cell proliferation via dose-dependent modulation of the mitogen-activated protein kinase pathway. Mol Cancer Res 2003; 1: 532-540.
24. Jozan S, Lafon C, Mathieu C et al. Enhancement of cisplatin cytotoxicity by all-trans retinoic acid in a human ovarian carcinoma cell line (OVCCR1) is characterized by apoptosis. Proc Am Assoc Cancer Res 1996; 37: 414 (Abstr).
25. Aebi S, Kröning R, Cenni B et al. All-trans retinoic acid enhances cisplatin-induced apoptosis in human ovarian adenocarcinoma and in squamous head and neck cancer cells. Clin Cancer Res 1997; 3: 2033-2038.
26. Jozan S, Paute S, Courtade-Saidi M et al. All trans retinoic acid enhances CDDP-induced apoptosis: Modulation of the CDDP effect on cell cycle progression. Int J Oncol 2002; 20: 1289-1295.
27. Wang Q, Wieder R. All-trans retinoic acid potentiates Taxotere-induced cell death mediated by Jun N-terminal kinase in breast cancer cells. Oncogene 2004; 23: 426-433.
28. Scribner DR Jr, Benbrook DM. Retinoids enhance cisplatin-based chemoradiation in cervical cancer cells in vitro. Gynecol Oncol 2002; 85: 223-225.
29. Sanz MA, Martin G, Diaz-Mediavilla J. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1998; 338: 393-394.
30. Farol LT, Hymes KB. Bexarotene: A clinical review. Expert Rev Anticancer Ther 2004; 4: 180-188.
31. Katsetos CD, Stadnicka I, Boyd JC et al. Cellular distribution of retinoic acid receptor-alpha protein in serous adenocarcinomas of ovarian, tubal, and peritoneal origin: Comparison with estrogen receptor status. Am J Pathol 1998; 153: 469-480.
32. Balli S, Fey MF, Hanggi W et al. Ovarian cancer. an institutional review of patterns of care, health insurance and prognosis. Eur J Cancer 2000; 36: 2061-2068.
33. Tavassoli FA, Devilee P. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press 2003.
34. Allred DC, Clark GM, Elledge R et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993; 85: 200-206.
35. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155-168.
36. Plisiecka-Halasa J, Karpinska G, Szymanska T et al. P21WAF1, P27KIP1, TP53 and C-MYC analysis in 204 ovarian carcinomas treated with platinum-based regimens. Ann Oncol 2003; 14: 1078-1085.
37. Cina SJ, Richardson MS, Austin RM, Kurman RJ. Immunohistochemical staining for Ki-67 antigen, carcinoembryonic antigen, and p53 in the differential diagnosis of glandular lesions of the cervix. Mod Pathol 1997; 10: 176-180.
38. Skirnisdottir I, Sorbe B, Seidal T. P53, bcl-2, and bax: Their relationship and effect on prognosis in early stage epithelial ovarian carcinoma. Int J Gynecol Cancer 2001; 11: 147-158.
39. Battifora H. Assessment of antigen damage in immunohistochemistry. The vimentin internal control. Am J Clin Pathol 1991; 96: 669-671.
40. Agresti A. Categorical Data Analysis, 2nd edn. Hoboken, NJ: Wiley-Interscience 2002.
41. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-481.
42. Cox DR. Regression models and life-tables (with discussion). J R Stat Soc Ser B 1972; 34: 187-220.
43. McGuire WP, Hoskins WJ, Brady ME et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
44. Piccart MJ, Bertelsen K, James K et al. Randomized Intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. J Natl Cancer Inst 2000; 92: 699-708.
45. Paclitaxel plus carboplatin. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial. Lancet 2002; 360: 505-515.
46. Sun S-Y, Hail N Jr, Lotan R. Apoptosis as a novel target for cancer chemoprevention. J Natl Cancer Inst 2004; 96: 662-672.
47. Lippman SM, Lee JJ, Karp DD et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst 2001; 93: 605-618.
48. Garcia AA, Morgan R, McNamara M et al. Phase II trial of fenretinide (4-HPR) in recurrent ovarian and primary peritoneal carcinoma: A California Cancer Consortium trial. Proc Am Assoc Cancer Res 2004; 23: 461.
49. Wang Q, Yang W, Uytingco MS et al. 1,25-Dihydroxyvitamin D3 and all-trans-retinoic acid sensitize breast cancer cells to chemotherapy-induced cell death. Cancer Res 2000; 60: 2040-2048.
50. Nehme A, Varadarajan P, Sellakumar G et al. Modulation of docetaxel-induced apoptosis and cell cycle arrest by all-trans retinoic acid in prostate cancer cells. Br J Cancer 2001; 84: 1571-1576.
51. Chakravarti N, Mathur M, Bahadur S et al. Retinoic acid receptor-alpha as a prognostic indicator in oral squamous cell carcinoma. Int J Cancer 2003; 103: 544-549.
52. Gyftopoulos K, Perimenis P, Sotiropoulou-Bonikou G et al. Immunohistochemical detection of retinoic acid receptor-alpha in prostate carcinoma: Correlation with proliferative activity and tumor grade. Int Urol Nephrol 2000; 32: 263-269.
53. van der Leede BM, Geertzema J, Vroom TM et al. Immunohistochemical analysis of retinoic acid receptor-alpha in human breast tumors: retinoic acid receptor-alpha expression correlates with proliferative activity. Am J Pathol 1996; 148: 1905-1914.
54. Zhu J, Gianni M, Kopf E et al. Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins. Proc Natl Acad Sci USA 1999; 96: 14807-14812.
55. Tanaka T, Rodriguez de la Concepcion ML, De Luca LM. Involvement of all-trans-retinoic acid in the breakdown of retinoic acid receptors alpha and gamma through proteasomes in MCF-7 human breast cancer cells. Biochem Pharmacol 2001; 61: 1347-1355.
56. Kastner P, Lawrence HJ, Waltzinger C et al. Positive and negative regulation of granulopoiesis by endogenous RARalpha. Blood 2001; 97: 1314-1320.
57. Soprano DR, Qin P, Soprano KJ. Retinoic acid receptors and cancers. Annu Rev Nutr 2004; 24: 201-221.
58. Zhang GY, Ahmed N, Riley C et al. Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma. Br J Cancer 2005; 92: 113-119.
59. Berg WJ, Nanus DM, Leung A et al. Up-regulation of retinoic acid receptor beta expression in renal cancers in vivo correlates with response to 13-cis-retinoic acid and interferon-alpha-2a. Clin Cancer Res 1999; 5: 1671-1675.
60. Esteva FJ, Glaspy J, Baidas S et al. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol 2003; 21: 999-1006.